Trial Profile
A randomized, 3-period, multiple-dose, multicenter study to evaluate the safety, tolerability, and plasma concentration profile of montelukast administered once daily as oral granules in children aged 3 to 6 months
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Asthma; Bronchiolitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck & Co; Organon
- 12 Nov 2006 New trial record.